Tirzepatide 5mg-120mg
-
Detail
Research Peptide · For Laboratory Use Only
Tirzepatide 10mg
Dual GIP/GLP-1 Receptor Agonist · 39-Amino-Acid Fatty-Acid-Conjugated Peptide · Lyophilized Powder · Purity ≥99% (HPLC)
Tirzepatide (development code LY3298176) is a synthetic 39-amino-acid linear peptide and the first-in-class dual GIP and GLP-1 receptor agonist — sometimes called a "twincretin". Its peptide backbone is based on the sequence of endogenous glucose-dependent insulinotropic polypeptide (GIP), modified with two α-aminoisobutyric acid (Aib) residues at positions 2 and 13 that confer resistance to dipeptidyl peptidase-4 (DPP-4) cleavage. A C20 fatty diacid moiety is conjugated to the lysine residue at position 20 through a hydrophilic linker, enabling strong reversible binding to plasma albumin and extending the elimination half-life to approximately 5 days — the basis of its once-weekly dosing profile.
By simultaneously engaging the GIP receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), tirzepatide became the landmark molecule of the dual-agonist incretin era: it was approved by the FDA in May 2022 (Mounjaro®) for type 2 diabetes and in November 2023 (Zepbound®) for chronic weight management, delivering in trials both superior glycemic control and greater weight reduction than selective GLP-1 agonists. Each vial is supplied as a sterile lyophilized (freeze-dried) powder to ensure maximum stability.
Product Specifications
Product Name Tirzepatide (LY3298176) CAS Number 2023788-19-2 Amino Acid Sequence H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys²⁰(AEEA-AEEA-γ-Glu-C20 diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ (39 residues based on the native GIP sequence; Aib = α-aminoisobutyric acid at positions 2 and 13; C-terminal amide) Molecular Formula C₂₂₅H₃₄₈N₄₈O₆₈ Molecular Weight 4813.53 Da (≈4.8 kDa) Receptor Profile Dual agonist at the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R); GIPR binding affinity comparable to native GIP Key Modifications Two Aib substitutions (DPP-4 resistance) · C20 fatty diacid conjugated to Lys-20 via hydrophilic linker (albumin binding, ~5-day half-life) Quantity 10mg per vial Physical Form White to off-white lyophilized powder Purity ≥99% as determined by HPLC Storage -20°C for long term; 2–8°C for short term (lyophilized) What is Tirzepatide?
The incretin system — the gut-derived hormonal response to nutrient intake — revolves around two key hormones: GIP (the dominant incretin, responsible for most of the insulin response to food) and GLP-1. For years, drug development focused on GLP-1 alone, because native GIP is rapidly inactivated and its role in metabolism was debated. Tirzepatide changed that paradigm by showing that co-activation of both receptors produces metabolic effects greater than either alone — a concept now widely referred to as the "twincretin" approach.
The molecule was engineered through rational peptide design. Its key structural features include:
- A GIP-based 39-amino-acid backbone, preserving the native GIP receptor pharmacophore while introducing residues that enhance GLP-1R cross-reactivity;
- Two Aib residues at positions 2 and 13, blocking cleavage by DPP-4 and related peptidases — the same stabilization strategy used across modern incretin analogs;
- A C20 fatty diacid on Lys-20 attached through a hydrophilic (AEEA-AEEA-γ-Glu) linker, producing ≈99% reversible plasma albumin binding that slows renal clearance and enzymatic degradation;
- A C-terminal amide, completing the linear sequence without disulfide bridges — a single-chain, non-cyclic design distinct from many other research peptides.
In published research, tirzepatide has been investigated in a wide range of settings, including:
- Type 2 diabetes research — the SURPASS clinical trial program demonstrated superior HbA1c reduction versus selective GLP-1 agonists and basal insulin comparators;
- Obesity and chronic weight management — the SURMOUNT program showed dose-dependent weight reduction of unprecedented magnitude for an incretin-based therapy, leading to the Zepbound® approval;
- GIP/GLP-1 receptor pharmacology — tirzepatide serves as the reference dual agonist for studying synergistic incretin signaling, including the ongoing scientific discussion of GIPR agonism versus antagonism in metabolic disease;
- Cardiometabolic and hepatic research, including studies in MASH (metabolic dysfunction-associated steatohepatitis) and obstructive sleep apnea models;
- Structure-activity relationship (SAR) studies, as its design principles guide the development of next-generation dual and triple incretin agonists.
As the first approved dual GIP/GLP-1 receptor agonist and one of the most clinically studied peptides of the last decade, tirzepatide has become the benchmark molecule against which all new incretin-based therapies are measured — a reference compound of central importance in metabolic research.
Mechanism of Action
Handling & Storage Guidelines
- Lyophilized powder: Store at -20°C for long-term stability; 2–8°C is acceptable for short-term storage. Avoid repeated temperature cycling and protect from light and moisture.
- Before opening: Allow the vial to reach room temperature and briefly centrifuge to ensure the full contents collect at the bottom of the vial.
- Reconstitution: Add bacteriostatic water or an appropriate solvent gently along the vial wall. Swirl slowly until fully dissolved; avoid vigorous shaking. As a large amphipathic peptide, tirzepatide can show slightly slower dissolution than small peptides — patient, gentle swirling is recommended.
- Reconstituted solution: Store at 2–8°C, protect from light, and use promptly; do not refreeze the solution.
- General: Handle with standard laboratory protective equipment (gloves, lab coat, eye protection).
Why Choose Our Tirzepatide?
🧪
Verified Purity
Each batch tested by HPLC & MS; COA available upon request.
📦
Secure Packaging
Sealed vials with temperature-protective packaging for safe delivery.
🚚
Fast Dispatch
Orders processed promptly with tracking provided.
Frequently Asked Questions
Q1: How is tirzepatide different from semaglutide?
A: The mechanisms differ. Semaglutide is a selective GLP-1 receptor agonist, while tirzepatide activates both GIP and GLP-1 receptors. Structurally, semaglutide is a GLP-1-based analog with a C18 fatty diacid, whereas tirzepatide is built on the GIP sequence with a C20 fatty diacid. In head-to-head clinical trials, the dual agonist showed superior glycemic and weight outcomes, which made tirzepatide the benchmark of the new dual-agonist era.
Q2: Why does tirzepatide contain the unusual amino acid Aib?
A: α-Aminoisobutyric acid (Aib) is a non-coded amino acid that cannot be recognized or cleaved by DPP-4 and most peptidases. Placing Aib at positions 2 and 13 dramatically extends the peptide's metabolic stability — a design principle shared by several modern long-acting peptides.
Q3: What is the purpose of the C20 fatty diacid?
A: The C20 fatty diacid attached to Lys-20 binds reversibly to plasma albumin (≈99% bound), shielding the peptide from enzymatic degradation and renal clearance. This extends the half-life to ~5 days and is what makes once-weekly dosing possible.
Q4: How should I store it after receiving?
A: Keep unopened vials at -20°C for long-term storage. Once reconstituted, refrigerate at 2–8°C, protect from light, and use promptly; do not refreeze the solution.
Q5: Is a Certificate of Analysis (COA) available?
A: Yes, third-party tested COA documentation can be provided for each batch. Please contact our customer service with your order number.
⚠ Research Use Only — Disclaimer
All product information provided on this page is solely for information dissemination and educational purposes. The products offered are intended exclusively for in vitro laboratory research and are not pharmaceuticals. They have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for the purposes sold here, and must not be used to prevent, treat or cure any medical condition, disease or ailment.
It is strictly prohibited to introduce these products into the human or animal body in any form. By purchasing, the buyer acknowledges full responsibility for the proper handling, use and compliance with all applicable local laws and regulations.
-
Customer ReviewsNo comments